Medical Doctor Program year 2020 Source: CMS Open Payments, 2026 publication

Pedro Rodriguez Benitez

Cardiovascular Disease Arecibo, PR Medical Doctor

NPI 1205898855 CMS profile 1080844

25 Calle P Mora Acosta, Arecibo, PR 00612

Open in the dashboard

General payments

$60

1 record reported · program year 2020

Research payments

$0

Paid to them · None reported · program year 2020

Ownership & investment interest

$0

None reported

Through program year 2020, Pedro Rodriguez Benitez of Arecibo, PR is reported in the CMS Open Payments database as having received $60 across 1 general payment and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 7th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

1 row
Year Kind Relative to this record's peak year Amount Records
2020 General $60 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Pedro Rodriguez Benitez
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Pedro Rodriguez Benitez were reported at $0. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Pedro Rodriguez Benitez Cardiovascular Disease median Middle half National median
2019 $0 $450 $127–$1,392 $163
2020 $60 $242 $77–$751 $114
2021 $0 $335 $101–$1,037 $132
2022 $0 $395 $121–$1,211 $149
2023 $0 $443 $136–$1,283 $160
2024 $0 $450 $136–$1,323 $164
2025 $0 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program year 2020
  1. Lilly USA, LLC $60 1 payment

Every payment, record by record

What the payments were for General payments · program year 2020
  1. Food and Beverage $60 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 14 drugs

Part D claims

459

Median for Cardiology: 2,533

Drug cost

$3,197

Median for Cardiology: $485,213

Branded share of claims

10%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Metoprolol Succinate Generic 54 $456
Losartan Potassium Generic 60 $417
Atorvastatin Calcium Generic 58 $386
Rosuvastatin Calcium Generic 44 $384
Amlodipine Besylate Generic 65 $260
Simvastatin Generic 42 $259
Isosorbide Mononitrate Er Isosorbide Mononitrate Brand 23 $182
Enalapril Maleate Generic 11 $177
Losartan-Hydrochlorothiazide Losartan/Hydrochlorothiazide Brand 12 $162
Nitroglycerin Generic 16 $132

The 10 drugs with the highest cost, of 14 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Records

1 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in Puerto Rico

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2020

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record